Baxter submits hemophilia drug for FDA approval

03/1/2013 | Pharmaceutical Business Review Online

Baxter International filed a biologics license application with the FDA for approval to use FEIBA NF Nanofiltered and Vapor Heated, its anti-inhibitor coagulant complex treatment, in patients with hemophilia A or B and inhibitors. The application was based on a late-stage trial that found routine prophylactic treatment was associated with a 72.5% decrease in bleeding rates.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC